Benefits and Obstacles to Neonatal Cell Therapy

The development of advanced cell‐based therapies offers a means to curb the complications associated with extreme preterm birth; however, while many early phase clinical trials have begun, their translation often fails. In a new STEM CELLS Translational Medicine article from researchers led by Bernard Thébaud (Ottawa Hospital Research Institute, Ottawa, Canada), the authors introduce the INCuBAToR concept (Innovative Neonatal Cellular Therapy for Bronchopulmonary Dysplasia: Accelerating Translation of Research) as an evidence‐based approach to mitigate the risks associated with translating cell‐based therapies into a vulnerable patient population.